Skip to main content

Table 1 Clinicopathological features and treatment of breast cancer patients followed by thyroid cancer and breast cancer alone patients (1stcohort)

From: The co-occurrence of both breast- and differentiated thyroid cancer: incidence, association and clinical implications for daily practice

Variables

BC‐TC (median (IQR)/%)

BC alone (median (IQR)/%)

p‐value

No. of patients

423

317579

 

BC clinical characteristics

   Age at BC diagnosis

55 (46-65)

60 (50-71)

< 0.001

   Female

423 (100)

315808 (99.4)

0.2

   Tumor size in mm

15 (10-25)

17 (11-25)

0.1

   Tumor site

   

      Left

223 (52.7)

164071 (51.7)

1

      Right

199 (47.0)

152907 (48.1)

 

      Unknown

1 (0.2)

601 (0.2)

   TNM stage

   

      0

38 (9.0)

29125 (9.2)

 

      I

154 (36.4)

112063 (35.3)

0.3

      II

176 (41.6)

122649 (38.6)

 

      III

43 (10.2)

33816 (10.6)

      IV

9 (2.1)

16746 (5.3)

      M

0 (0.0)

1562 (0.5)

      Unknown

3 (0.7)

1618 (0.5)

   ER-positivity

201 (87.41)

151727 (82.61)

0.1

   PR-positivity

154 (67.81)

120837 (67.01)

0.8

   HER2-positivity

35 (17.51)

23810 (14.81)

0.5

   BC surgery2

406 (96.0)

286592 (90.2)

<0.001

      Breast-conserving

226 (53.3)

163501 (51.5)

 

      Ablative

168 (39.7)

13995 (35.9)

      Surgery NNO

12 (2.8)

8867 (2.8)

   BC radiation therapy

270 (63.8)

186779 (58.8)

0.04

   BC chemotherapy

158 (37.4)

97895 (30.8)

<0.001

   BC hormone therapy

191 (45.2)

140908 (44.4)

0.7

TC clinical characteristics

   Age at TC diagnosis

62 (52-72)

  

   Tumor size in mm

15 (8-25)

  

   Papillary thyroid cancer

331 (78.3)

  

   Follicular thyroid cancer

81 (19.1)

  

   Unknown histology

11 (2.6)

  

   Lymph node metastasis

98 (23.2)

  

   Distant metastasis

11 (2.6)

  
  1. 1 Missings substracted
  2. 2 Missing patients